Clinical Trials
2 trialsNCT03111992 2022-02-09
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT02331368 2018-07-27
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed